Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2026-02-25 | 2026-02-25 |
| Drug Identification Number | 02230640 | 02230640 |
| Brand name | TOBRAMYCIN INJECTION | TOBRAMYCIN INJECTION |
| Common or Proper name | Tobramycin Injection, USP 40 mg/mL, 30 mL Vial | Tobramycin Injection, USP 40 mg/mL, 30 mL Vial |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | TOBRAMYCIN | TOBRAMYCIN |
| Strength(s) | 40MG | 40MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 30 mL | 30 mL |
| Additional packaging sizes | ||
| ATC code | J01GB | J01GB |
| ATC description | AMINOGLYCOSIDE ANTIBACTERIALS | AMINOGLYCOSIDE ANTIBACTERIALS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2026-03-31 | 2026-03-31 |
| Actual start date | ||
| Estimated end date | 2026-04-20 | 2026-04-20 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that, due to production delays we will encounter a backorder on our Tobramycin Injection, USP 40 mg/mL, 30 mL vial from April 1, 2026, until April 20, 2026. As previously communicated, all current inventory is short-dated and expires on March 31, 2026. Please continue to order the short-dated product while available. | Fresenius Kabi Canada regrets to advise that, due to production delays we will encounter a backorder on our Tobramycin Injection, USP 40 mg/mL, 30 mL vial from April 1, 2026, until April 20, 2026. As previously communicated, all current inventory is short-dated and expires on March 31, 2026. Please continue to order the short-dated product while available. |
| Health Canada comments |